Print Friendly
E-mail Page
Share PageOffice of Technology Management and Development
The Salk Institute's Office of Technology Management and Development (OTMD) supports the Institute by managing intellectual property discovered by Institute scientists. This intellectual property advances the Institute's mission to improve human health by transferring basic research discoveries made in the laboratories to the marketplace for commercial development. To that end, OTMD works with the faculty to begin the patenting process for research discoveries, negotiates and administers technology licenses, and facilitates industry collaboration and sponsored research.
Technology management at the Institute has resulted in over 350 U.S. patents and more than 250 license agreements with pharmaceutical, biotechnology, and reagent supply companies. In addition, 22 startup companies have been founded to develop Institute technology, including Ligand Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Signal Pharmaceuticals (acquired by Celgene Corporation) and SIBIA Neursciences (acquired by Merck and Co., Inc.). OTMD is also fostering new startup activity for technologies to treat diabetes and neurological diseases, as well as for understanding the effects of aging.
New Technologies
- Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro
- Good fences make good neighbors: Missing genomic "fence posts" explain inactivated tumor suppressor genes in breast cancer
- Salk scientists detect molecular obesity link to insulin resistance, type II diabetes
- Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers
- New pathway is common thread in age related neurodegenerative diseases
- Newborn brain cells "time stamp" memories
- Salk researchers develop novel glioblastoma mouse model